Source disclosure: February 10, 2026
Kubota Pharmaceutical Holdings Co., Ltd. [4596.T]
TOKYO, Feb 10 (Pulse News Wire) – Kubota Pharmaceutical Holdings CO.,LTD. (4596.T) revised its fiscal year 2025 (January 1, 2025 to December 31, 2025) consolidated performance forecast due to increased marketing costs and research and development expenses.
According to the latest estimates, the company anticipates consolidated revenue of ¥21 million, operating profit of --¥877 million, pre-tax income of --¥659 million, net profit of --¥659 million, and earnings per share of -. Compared to previous forecasts, these figures reflect a significant impact from ongoing investments in product promotion and next-generation technology development. In particular, the "Kubota Glass®" initiative focuses on enhancing domestic awareness and expanding sales channels in Asia and Europe.
Despite these efforts, the company expects to incur an operational loss of 877 million yen due to substantial investment in marketing activities and R&D. However, non-operating gains are anticipated to mitigate some of the losses below the net profit level. Looking ahead, Kubota Pharmaceutical plans to explore innovative distribution methods in the Japanese market to sustainably deliver the value of Kubota Glass.
Additionally, the company remains committed to advancing the "Emicstat Hydrochloride" project through global partnerships, aiming to achieve profitability and early black ink status.
AI-translated content. 🟢 Confidence: High See terms • Original filing